2 May 2024 - Amolyt Pharma today announced that eneboparatide, its lead therapeutic peptide candidate in Phase 3 development for the treatment of hypoparathyroidism, has been granted fast track designation by the US FDA.

Eneboparatide is an investigational therapeutic peptide designed to bind with high affinity to a specific conformation of the parathyroid hormone receptor to produce sustained and stable levels of calcium in the blood and thereby manage the symptoms of hypoparathyroidism, and to limit urine calcium excretion by restoring calcium reabsorption by the kidney, with the goal of consequently preventing progressive decline in kidney function and the development of chronic kidney disease.

Read Amolyt Pharma press release